Lilian Arnaud

Lilian Arnaud

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
AAAria Assefi
Aria Assefi
PDPaula Van Dommelen
Paula Van Dommelen
LALilian Arnaud
Lilian Arnaud
COCarlos Otero
Carlos Otero
LLLuis Luque
Luis Luque
LCLuis Eduardo Calliari
Luis Eduardo Calliari
Background: Recombinant human growth hormone (rhGH) therapy is an effective treatment for children with growth disorders. However, poor outcomes are often associated with suboptimal adherence to treatment. Objective: The easypod connected injection device records and transmits injection settings and dose data from patients receiving rhGH. In this study, we evaluated adherence to rhGH treatment, and associated growth outcomes, in Latin American patients. Methods: Adherence and growth data from patients aged 2-18 years from 12 Latin American countries were analyzed. Adherence data were available for 6207 patients with 2,449,879 injections, and growth data were available for 497 patients with 2232 measurements. Adherence was categorized, based on milligrams of rhGH injected versus milligrams of rhGH prescribed, as high (≥85%), intermediate (>56%-<85%), or low (≤56%). Transmission frequency was categorized as high (≥1 per 3 months) or low (<1 per 3 months). Chi-square tests were applied to study the effect of pubertal status at treatment start and sex on high adherence, and to test differences in frequency transmission between the three adherence levels. Multilevel linear regression techniques were applied to study the effect of adherence on observed change in height standard deviation score (∆HSDS). Results: Overall, 68% (4213/6207), 25% (n=1574), and 7% (n=420) of patients had high, intermediate, and low adherence, respectively. Pubertal status at treatment start and sex did not have a significant effect on high adherence. Significant differences were found in the proportion of patients with high transmission frequency between high (2018/3404, 59%), intermediate (608/1331, 46%), and low (123/351, 35%) adherence groups (P<.001). Adherence level had a significant effect on ∆HSDS (P=.006). Mean catch-up growth between 0-24 months was +0.65 SD overall (+0.52 SD in patients with low/intermediate monthly adherence and +0.69 SD in patients with high monthly adherence). This difference translated into 1.1 cm greater catch-up growth with high adherence. Conclusions: The data extracted from the easypod Connect ecosystem showed high adherence to rhGH treatment in Latin American patients, with positive growth outcomes, indicating the importance of connected device solutions for rhGH treatment in patients with growth disorders.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
ASAmalia Spataru
Amalia Spataru
PDPaula Van Dommelen
Paula Van Dommelen
LALilian Arnaud
Lilian Arnaud
QMQuentin Le Masne
Quentin Le Masne
SQSilvia Quarteroni
Silvia Quarteroni
EKEkaterina B Koledova
Ekaterina B Koledova
Background: Long-term persistence of use and starting at the earliest possible age are associated with attainment of near-normal adult or final height in children who are treated with growth hormone therapy. However, there are many factors associated with a lack of persistence. Our aim was to study persistence of use in children with growth disorders using the easypod™ connected autoinjector e-device, which automatically records adherence data and can transmit them via an online portal (easypod™ connect). We investigated persistence of use, defined indicators of a long persistence of use, and developed a model to predict and identify children at risk of discontinuing treatment in the following 6 months. Data and Methods: Anonymized data from children transmitting over 10 injections between January 2007 and April 2020 were analyzed. A child was considered to discontinue the use if they had no injection in the last 6 months (before April 2020) or had an injection pause of at least 6 consecutive months. Persistence was estimated by Kaplan-Meier analyses and Weibull accelerated failure time modeling. To predict the individual risk of discontinuing the use in the following 6 months, individual survival probabilities curves were estimated for each patient still using the system, and the survival probabilities were then recalculated such that they were conditional on the fact that a child had already used the device for a certain time. The Harrell’s c-index was used to assess the algorithm performance. Results: Data were available for 17,651 children of whom 11,056 discontinued the use and 6,595 were still persistent in April 2020. Median persistence of use for all patients using the device was 2.1 years. There was a highly significant difference in median persistence of use between the regions: 1.0, 1.5 and 2.8 years in the available countries in the Asia-Pacific, America and Europe regions, respectively. Other indicators that had a significant positive impact on persistence of use were: at least one dose change a year, having auxological measurements recorded in the system (and if ‘Yes’, height standard deviation < -2 at start of use had an additional effect), starting treatment at an early age, adherence ≥85%, customized injection speed setting and being male. For the individual prediction, random survival forests showed the best performance (Harrell’s c-index=0.72). Conclusions: Data from the connected autoinjector e-device showed that the persistence of use was approximately 2 years in children with growth disorders. We were able to define 8 indicators that had a positive impact on persistence of use of which several indicators were related to patient management. Our prediction model can be used to identify children needing support to reach longer persistence of use and subsequently optimal clinical outcomes.

22 October 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
MPMichel Polak
Michel Polak
NBNatacha Bouhours-Nouet
Natacha Bouhours-Nouet
PDPaula Van Dommelen
Paula Van Dommelen
LALilian Arnaud
Lilian Arnaud
SBSophie Berger
Sophie Berger
ALAgnes Linglart
Agnes Linglart
Context: Adherence to recombinant GH treatment is crucial to achieve optimal adult height in children with growth disorders. Information on factors responsible for differences in adherence and growth in different countries is limited. Aim: To evaluate adherence and catch-up growth in children receiving GH using Easypod® auto-injectors. Methods: Retrospective cohort analysis of adherence and height, from 481 children (55% boys) in 19 centers in France, from the Growzen® Connect database, from mid-2018 to end-2023. Adherence was classified as high (≥85% of injections) or medium/low ( .5). For children with high adherence, 2-year HSDS gain was significantly higher than for children with lower adherence (0.8 vs +0.5, P = .030). Conclusion: Children using Easypod exhibit high adherence, which aids clinical decision-making and patient engagement. Adherence and catch-up growth decrease with age. Indication for GH treatment had little impact, but overall catch-up growth was significantly greater with high adherence.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
ASAmalia Spataru
Amalia Spataru
PDPaula Van Dommelen
Paula Van Dommelen
LALilian Arnaud
Lilian Arnaud
QMQuentin Le Masne
Quentin Le Masne
SQSilvia Quarteroni
Silvia Quarteroni
EKEkaterina B Koledova
Ekaterina B Koledova
Background: Suboptimal adherence to recombinant human growth hormone (r-hGH) treatment can lead to suboptimal clinical outcomes. Being able to identify children who are at risk of suboptimal adherence in the near future, and take adequate measures to support adherence, may maximize clinical outcomes. Our aim was to develop a model based on data from the first 3 months of treatment to identify potential indicators of suboptimal adherence and predict adherence over the following 9 months using a machine learning approach. Methods: We assessed adherence to r-hGH treatment in children with growth disorders in their first 12 months of treatment using a connected autoinjector and e-device (easypod™), which automatically transmits adherence data via an online portal (easypod™ connect). We selected children who started the use of the device before 18 years of age and who transmitted their injection data for at least 12 months. Adherence (mg injected/mg prescribed) between 4-12 months (outcome) was categorized as optimal (≥85%) versus suboptimal (<85%). In addition to adherence over the first 3 months, comfort settings (needle speed, injection depth, injection speed, injection time), number of transmissions, number of dose changes, age at start and sex were used as potential indicators of suboptimal adherence. Several machine learning models were optimized on a class-balanced training dataset using a 5-fold cross-validation scheme. On the best performing model, machine learning interpretation techniques and chi-squared statistical tests were applied to extract the statistically significant indicators of suboptimal and optimal adherence. Results: Anonymized data were available for 10,943 children. The optimal prediction performances were achieved with the random forest algorithm. The mean adherence and the adherence standard deviation over the first 3 months were the two most important features for predicting adherence in the following 9 months. Not using the system’s features (e.g. not transmitting data often and not changing some of the comfort settings, such as the needle speed setting), as well as starting treatment at an older age were significantly associated with an increased risk of suboptimal adherence (p<0.001). When tested on first-time seen data following the same class distribution as the original data, the model achieved a sensitivity of 80% and a specificity of 81%. Conclusions: We developed a model predicting whether a child’s adherence in the following 9 months will be below or above the optimal threshold (85%) based on early data from the first 3 months of treatment and we identified the indicators of suboptimal adherence. These results can be used to identify children needing additional medical or other support to reach optimal adherence and therefore optimal clinical outcomes.

3 June 2023 in Expert Opinion on Drug Delivery
Verified
Journal Article
Open access
FPFrancesco Piras
Francesco Piras
LALilian Arnaud
Lilian Arnaud
EHEric Henninger
Eric Henninger
MKMatthew Keiser
Matthew Keiser
ASAndrea Seitzinger
Andrea Seitzinger
QMQuentin Le Masne
Quentin Le Masne
Self-administration of subcutaneous interferon beta-1a (sc IFN β-1a) can be achieved with the RebiSmart® electromechanical autoinjector. This study investigated adherence to, and duration of persistence with, the newest version of the device (v1.6) among 2644 people receiving sc IFN β-1a for multiple sclerosis (MS). This retrospective, observational study utilized data from RebiSmart® devices, recorded on the MSdialog database, between January 2014 and November 2019. Adherence and persistence were evaluated over a 3-year period and assessed in relation to age, sex, injection type, and injection depth. The population of RebiSmart® users (N = 2644) comprised of 1826 (69.1%) females and mean age was 39 (range 16-83) years. Adherence to RebiSmart® use and data transfer to the MSdialog database was consistently high (mean 91.7%; range 86.8-92.6%), including across all variables (81.6-100%). Mean (±SD) persistence during the study period was 1.35 ± 1.06 years, with a maximum recorded persistence of 5.1 years. In multivariate analysis, the longest durations of persistence were observed among older individuals and males (p < 0.0001 and p = 0.0078, respectively). People living with MS were highly adherent to use of the RebiSmart® device, with higher persistence generally observed for older and/or male individuals.

21 May 2026
Verified
Book Chapter
Open access
PDPaula Van Dommelen
Paula Van Dommelen
LALilian Arnaud
Lilian Arnaud
AAAntonio de Arriba-Muñoz
Antonio de Arriba-Muñoz
EKEkaterina Koledova
Ekaterina Koledova
MCMaria Lourdes Crespo
Maria Lourdes Crespo
IBIgnacio Bergadá
Ignacio Bergadá
The Growzen® Connect digital ecosystem has been developed to support treatment for patients on recombinant human growth hormone (r-hGH) therapy. This ecosystem includes electronic injection devices with adherence data transmitters and a platform for healthcare professionals (HCPs) to monitor real-time patient adherence. This study aimed to investigate whether HCPs’ engagement with this platform influences adherence to r-hGH therapy in patients from Spain in Argentina. Adherence data (optimal [≥85%] versus suboptimal [<85%]) in the first four years of treatment at the patient level and three clinic-level metrics were extracted from the platform in the year 2024. Patients from Spain and Argentina were selected. We defined three metrics for digital engagement: frequency of monitoring adherence, height data entry, and reported dose changes. Adherence data were obtained from 4,544 patients in 186 clinics in Spain, and 1,550 patients in 184 clinics in Argentina. The proportion of patients with optimal adherence was higher in clinics where HCPs digitally monitored patient adherence data more often, entered more height data in the platform, and more often reported a change in dose. Our research revealed that HCPs’ engagement with a digital adherence monitoring platform positively influenced patient adherence to r-hGH therapy in Spain and Argentina.